PHARMACOECONOMIC ANALYSIS OF AXITINIB AS SECOND-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA

被引：0
|
作者：
Kulikov, A. [1 ]
Komarov, I [1 ]
机构：
[1] First Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2299
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN141
引用
收藏
页码：A638 / A639
页数：2
相关论文
共 50 条
  • [1] Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma
    Ueda, Kosuke
    Suekane, Shigetaka
    Hirano, Taishi
    Ogasawara, Naoyuki
    Chikui, Katsuaki
    Uemura, Keiichiro
    Nakiri, Makoto
    Nishihara, Kiyoaki
    Matsuo, Mitsunori
    Igawa, Tsukasa
    [J]. ANTICANCER RESEARCH, 2018, 38 (09) : 5387 - 5392
  • [2] Axitinib in metastatic renal cell carcinoma: beyond the second-line setting
    Umeyama, Yoshiko
    Shibasaki, Yoshiyuki
    Akaza, Hideyuki
    [J]. FUTURE ONCOLOGY, 2017, 13 (21) : 1839 - 1852
  • [3] Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma
    Nakai, Yasutomo
    Takeuchi, Ario
    Osawa, Takahiro
    Kojima, Takahiro
    Hara, Tomohiko
    Sugimoto, Mikio
    Eto, Masatoshi
    Minami, Keita
    Ueda, Kosuke
    Ozawa, Michinobu
    Uemura, Motohide
    Miyauchi, Yasuyuki
    Ohba, Kojiro
    Kashiwagi, Akira
    Murakami, Masaya
    Sazuka, Tomokazu
    Yasumoto, Hiroaki
    Morizane, Shuichi
    Kawasaki, Yoshihide
    Morooka, Daichi
    Shimazui, Toru
    Yamamoto, Yoshiaki
    Nakagomi, Hiroshi
    Tomida, Ryotaro
    Ito, Yoichi M.
    Murai, Sachiyo
    Kitamura, Hiroshi
    Nishiyama, Hiroyuki
    Shinohara, Nobuo
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 834 - 837
  • [4] PHARMACOECONOMIC ANALYSIS OF THE USE OF EVEROLIMUS COMPARED TO AXITINIB IN SECOND LINE THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Kolbin, A.
    Frolov, M.
    Kurylev, A.
    Balykina, Y.
    Proskurin, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A442 - A442
  • [5] Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study
    Huang, Jiwei
    Shi, Guohai
    Wang, Yueming
    Wang, Ping
    Zhang, Jin
    Kong, Wen
    Huang, Yiran
    Wang, Shuo
    Xue, Wei
    [J]. FUTURE ONCOLOGY, 2022, 18 (12) : 1461 - 1471
  • [6] Real-world experience of axitinib as second-line treatment in metastatic renal cell carcinoma: Analysis of the Swedish population.
    Strambi, Angela
    Jakobsson, Maria
    Nilsson, Fredrik
    Arpegard, Johannes
    Dalen, Johan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [7] Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population
    Jakobsson, Maria
    Strambi, Angela
    Nilsson, Fredrik
    Arpegard, Johannes
    Dalen, Johan
    [J]. FUTURE ONCOLOGY, 2024, 20 (20) : 1385 - 1392
  • [8] Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
    Geczi, Lajos
    Bodoky, Gyorgy
    Rokszin, Gyorgy
    Fabian, Ibolya
    Torday, Laszlo
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2201 - 2207
  • [9] COST OF CARE WITH EVEROLIMUS VERSUS AXITINIB FOR SECOND-LINE METASTATIC RENAL CELL CARCINOMA PATIENTS IN CANADA
    Perrin, A.
    Chua, A.
    Wang, X.
    Hurry, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A402 - A402
  • [10] THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING CABOZANTINIB AS SECOND-LINE THERAPY FOR ADULT PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN RUSSIA
    Krysanova, V
    Krysanov, I
    Ermakova, V
    [J]. VALUE IN HEALTH, 2020, 23 : S448 - S448
12345